Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 436 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Today is Giving Tuesday December 1, 2020 Long-Term Follow-Up Confirms a Sustained Reduction in Deaths from Prostate Cancer... November 4, 2025 EMA Recommends Granting a Conditional Marketing Authorisation for Repotrectinib November 27, 2024 How Financial Toxicity Can Impact Cancer Caregivers and Where to Find... August 23, 2022 Load more HOT NEWS Building a Support Community During Cancer: “Your Stories” Podcast Bean there done that: Can swapping to pulses be the new... 74 & 75-Year-Old Sweethearts Get Married In ICU In Wake Of... Enhertu May Be Preferred Therapy for Some Metastatic Breast Cancers
